DILH
RARE icon

Dai-ichi Life Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dai-ichi Life Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,221
Closed -$867K – 364
2016
Q3 		$867K Sell
12,221
-7,402
-38% -$472K 0.03% 419
2016
Q2 		$960K Buy
+19,623
New +$1.27M 0.03% 400

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dai-ichi Life Holdings's RARE Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 12,221 shares — an estimated $867K sold.

Dai-ichi Life Holdings first reported a position in RARE in Q2 2016 and held it in 2 quarters. The position peaked at $960K in Q2 2016. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 12,221 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $867K.
  • Dai-ichi Life Holdings first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and held it in 2 quarters.
  • Dai-ichi Life Holdings's Ultragenyx Pharmaceutical position peaked at $960K in Q2 2016.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.